Vitesse Gains Speed With First Venture, Built On Astellas Asset
This article was originally published in PharmAsia News
Astellas is continuing to divest non-core pipeline assets, this time a candidate for B-cell disorders including lupus, which will be the basis of the first venture to be formed by Baxalta-affiliated Vitesse Biologics.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.